| Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder M Kuloglu, B Ustundag, M Atmaca, H Canatan, AE Tezcan, N Cinkilinc Cell biochemistry and function 20 (2), 171-175, 2002 | 430 | 2002 |
| Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics M Atmaca, M Kuloglu, E Tezcan, B Ustundag Journal of Clinical Psychiatry 64 (5), 598-604, 2003 | 311 | 2003 |
| Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder M Atmaca, S Kumru, E Tezcan Human Psychopharmacology: Clinical and Experimental 18 (3), 191-195, 2003 | 251 | 2003 |
| Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder M Kuloglu, M Atmaca, E Tezcan, Ö Gecici, H Tunckol, B Ustundag Neuropsychobiology 46 (1), 27-32, 2002 | 245 | 2002 |
| The classification of obsessive–compulsive and related disorders in the ICD-11 DJ Stein, CS Kogan, M Atmaca, NA Fineberg, LF Fontenelle, JE Grant, ... Journal of affective disorders 190, 663-674, 2016 | 241 | 2016 |
| The anxiety levels, quality of sleep and life and problem-solving skills in healthcare workers employed in COVID-19 services S Korkmaz, A Kazgan, S Çekiç, AS Tartar, HN Balcı, M Atmaca Journal of Clinical Neuroscience 80, 131-136, 2020 | 238 | 2020 |
| Impulse control disorders and “behavioural addictions” in the ICD-11 JE Grant, M Atmaca, NA Fineberg, LF Fontenelle, H Matsunaga, ... World Psychiatry 13 (2), 125, 2014 | 234 | 2014 |
| Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study M Atmaca, M Kuloglu, E Tezcan, O Gecici International clinical psychopharmacology 17 (3), 115-119, 2002 | 234 | 2002 |
| Volumetric MRI study of key brain regions implicated in obsessive–compulsive disorder M Atmaca, H Yildirim, H Ozdemir, E Tezcan, AK Poyraz Progress in neuro-psychopharmacology and Biological Psychiatry 31 (1), 46-52, 2007 | 219 | 2007 |
| Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study S Bulut, MS Berilgen, A Baran, A Tekatas, M Atmaca, B Mungen Clinical neurology and neurosurgery 107 (1), 44-48, 2004 | 191 | 2004 |
| Antioxidant enzyme and malondialdehyde levels in patients with panic disorder M Kuloglu, M Atmaca, E Tezcan, B Ustundag, S Bulut Neuropsychobiology 46 (4), 186-189, 2003 | 189 | 2003 |
| Serum leptin and cholesterol values in suicide attempters M Atmaca, M Kuloglu, E Tezcan, B Ustundag, O Gecici, B Firidin Neuropsychobiology 45 (3), 124-127, 2002 | 142 | 2002 |
| The impact of red blood cell distribution width and neutrophil/lymphocyte ratio on the diagnosis of major depressive disorder F Demircan, N Gözel, F Kılınç, R Ulu, M Atmaca Neurology and therapy 5, 27-33, 2016 | 129 | 2016 |
| The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study M Atmaca, M Kuloglu, E Tezcan, A Semercioz International journal of impotence research 14 (6), 502-505, 2002 | 127 | 2002 |
| Serum leptin and cholesterol levels in patients with bipolar disorder M Atmaca, M Kuloglu, E Tezcan, B Ustundag, Y Bayik Neuropsychobiology 46 (4), 176-179, 2003 | 125 | 2003 |
| A case of problematic internet use successfully treated with an SSRI-antipsychotic combination M Atmaca Progress in Neuro-Psychopharmacology and Biological Psychiatry 31 (4), 961-962, 2007 | 119 | 2007 |
| Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts M Atmaca, M Kuloglu, E Tezcan, B Ustundag Acta Psychiatrica Scandinavica 108 (3), 208-214, 2003 | 118 | 2003 |
| Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment M Atmaca, E Tezcan, M Kuloglu, B Ustundag, H Tunckol European Archives of Psychiatry and Clinical Neuroscience 254, 231-235, 2004 | 114 | 2004 |
| Volumetric MRI assessment of brain regions in patients with refractory obsessive–compulsive disorder M Atmaca, H Yildirimb, H Ozdemirb, A Aydinb, E Tezcana, S Ozlera Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 (6), 1051-1057, 2006 | 112 | 2006 |
| Hippocampus and amygdalar volumes in patients with refractory obsessive–compulsive disorder M Atmaca, H Yildirim, H Ozdemir, S Ozler, B Kara, Z Ozler, E Kanmaz, ... Progress in neuro-psychopharmacology and Biological Psychiatry 32 (5), 1283-1286, 2008 | 110 | 2008 |
